Animal worming tablets ineffective as cancer therapy: MFDS (2019)

News Report · Lim Jeong-yeo (The Korea Herald), reporting the Ministry of Food and Drug Safety and the Korean Cancer Association · October 28, 2019

Lim Jeong-yeo (The Korea Herald), 2019-10-28: Korea Herald report of the October 2019 Korean fenbendazole episode: the Ministry of Food and Drug Safety and the Korean Cancer Association publicly said using the veterinary dewormer as cancer treatment is inappropriate, citing the absence of human clinical data, while terminal patients livestreamed their self-experiments on YouTube.

Using fenbendazole, a broad-spectrum drug used by veterinarians against gastrointestinal parasites –administered to sheep, cattle, horses, fish, dogs, cats, rabbits, and seals — as treatment for cancer patients is inappropriate, the Korean Cancer Association and Ministry of Food and Drug Safety said Monday, citing lack of clinical data

Lim Jeong-yeo (The Korea Herald), 2019-10-28: Korea Herald report of the October 2019 Korean fenbendazole episode: the Ministry of Food and Drug Safety and the Korean Cancer Association publicly said using the veterinary dewormer as cancer treatment is inappropriate, citing the absence of human clinical data, while terminal patients livestreamed their self-experiments on YouTube. News report (secondary), quoting the Korean regulator and cancer association; recorded as the published coverage of the 2019 fad. Details in the article: fenbendazole sold online at 42,000 won (about US$36) for six tablets; authorities noted that 'the oncological effects of fenbendazole is based on experiments conducted on cells and animals, not humans'. The MFDS's own press release was not located on the MFDS site during this run (see Run Notes) – SOURCE NOT FOUND for the primary regulatory text, so the news report is recorded instead. Korean-language coverage also exists (Kyunghyang Shinmun 2019-11-03; Korea Biomedical Review). Study type: news.